Allas S, Ovize M, Culler MD, et al. A single administration of AZP-3601, a novel, long-acting PTH analog, induces a significant and sustained calcemic response: preliminary data from a randomized, double-blind, placebo-controlled phase 1 study. Presented at: the Endocrine Society (ENDO) 2021 Meeting; March 20-23, 2021; Virtual. Poster.
Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317-2337.
Bollerslev J, Rejnmark L, Marcocci C, et al; European Society of Endocrinology. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015;173:G1-G20.
Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. J Clin Endocrinol Metab. 2016;101:2273-2283.
Gafni R. The effects of encaleret (CLTX-305) on mineral physiology in adh1 demonstrate proof-of-concept: early results from an ongoing phase 2b, open-label, dose-ranging study. Presented at: the Endocrine Society (ENDO) 2021 Meeting; March 20-23, 2021; Virtual. Poster 8545.
Gardella TJ, Vilardaga JP. International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors. Pharmacol Rev. 2015;67:310-337.
Karpf DB, Pihl S, Mourya S, et al. A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults. J Bone Miner Res. 2020;35:1430-1440.
Khan AA, Koch CA, Van Uum S, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019;180:P1-P22.
Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1:275-283.
Mantovani G, Bastepe M, Monk D, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat Rev Endocrinol. 2018;14:476-500.
Meola A, Vignali E, Matrone A, et al. Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest. 2018;41:1221-1226.
Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507-4514.
Nishimura Y, Esaki T, Isshiki Y, et al. Lead optimization and avoidance of reactive metabolite leading to PCO371, a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) agonist. J Med Chem. 2020;63:5089-5099.
Rejnmark L, Sikjaer T, Underbjerg L, et al. PTH replacement therapy of hypoparathyroidism. Osteoporos Int. 2013;24:1529-1536.
Rizzoli R. Hypoparathyroidism during magnesium deficiency or excess. In: Brandi ML, Brown EM. Hypoparathyrodism. 2015. Springer Nature Switzerland AG; 397-403.
Rubin M, Rejnmark L, Schwarz P, et al. TransCon PTH as a hormone replacement therapy for patients with hypoparathyroidism: 6-month update from the PaTH forward open-label extension. Presented at: the Endocrine Society (ENDO) 2021 Meeting; March 20-23, 2021; Virtual. Presentation.
Rubin MR, Cusano NE, Fan WW, et al. Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101:2742-2750.
Shimizu M, Joyashiki E, Noda H, et al. Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys. J Bone Miner Res. 2016;31:1405-1412.
Sikjaer T, Rejnmark L, Rolighed L, et al; Hypoparathyroid Study Group. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358-2370.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Aliya Khan, MD, FRCPC, FACP, FACE

Professor of Clinical Medicine
Divisions Endocrinology and Metabolism and Geriatrics
Director, Fellowship in Metabolic Bone Disease
Director, Calcium Disorders Clinic
McMaster University
Hamilton, Ontario, Canada

Disclosures

Disclosure: Aliya Khan, MD, FRCPC, FACP, FACE, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Amolyt; Takeda; Ultragenyx
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Ultragenyx
Received grants for clinical research from: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Ascendis Pharma; Radius Health, Inc.; Takeda; Ultragenyx

Editor

Anne G. Le, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

The following SPC member who planned and reviewed content for this activity reported the following relevant financial relationships:

Kelly Lauter Roszko, MD, PhD:
The National Institute of Dental and Craniofacial Research (NIDCR) receives financial support from Calcilytix and Amgen for research investigating pharmaceutical agents.
I am an unpaid consultant to Bayer and Calcilytix.

The following SPC Committee members reported financial relationships:

Andjela T. Drincic, MD: Advisory Board Member, Corcept

Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member

Amy Rothberg, MD: Spouse, consultant of Merck

Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD; Neena Natt, MD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME

A New Path Forward? Where Are We Going in Managing Hypoparathyroidism?

Authors: Aliya Khan, MD, FRCPC, FACP, FACE
CME Released: 4/29/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/29/2022

Start Activity

Target Audience and Goal Statement

This activity is intended for diabetologists & endocrinologists and primary care physicians.

The goal of this activity is to educate endocrinologists and others who treat hypoparathyroidism about new/emerging options for management.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Current state of the art and gaps in management of hypoparathyroidism
- Emerging treatments for the management of hypoparathyroidism

Disclosures

Faculty

Aliya Khan, MD, FRCPC, FACP, FACE

Professor of Clinical Medicine
Divisions Endocrinology and Metabolism and Geriatrics
Director, Fellowship in Metabolic Bone Disease
Director, Calcium Disorders Clinic
McMaster University
Hamilton, Ontario, Canada

Disclosures

Disclosure: Aliya Khan, MD, FRCPC, FACP, FACE, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Amolyt; Takeda; Ultragenyx
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Ultragenyx
Received grants for clinical research from: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Ascendis Pharma; Radius Health, Inc.; Takeda; Ultragenyx

Editor

Anne G. Le, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Anne G. Le, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

The following SPC member who planned and reviewed content for this activity reported the following relevant financial relationships:

The following SPC Committee members reported financial relationships:

Andjela T. Drincic, MD: Advisory Board Member, Corcept

Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member

Amy Rothberg, MD: Spouse, consultant of Merck

Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:

Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD; Neena Natt, MD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The staff involved in the development of this CME activity reported no relevant financial relationships

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Developed through a collaboration between the Endocrine Society and Medscape Education.

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

For Physicians

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved accreditation with commendation.

The Endocrine Society designates this online activity for a maximum of 0.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Diabetes & Endocrinology

CME

A New Path Forward? Where Are We Going in Managing Hypoparathyroidism?

Authors: Aliya Khan, MD, FRCPC, FACP, FACEFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 4/29/2021

Valid for credit through: 4/29/2022

processing....

CME Information Download Slides

Full Live Event Audio

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Aliya Khan, MD, FRCPC, FACP, FACE

Editor

Anne G. Le, PharmD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CME

A New Path Forward? Where Are We Going in Managing Hypoparathyroidism?

Target Audience and Goal Statement

Disclosures

Faculty

Aliya Khan, MD, FRCPC, FACP, FACE

Editor

Anne G. Le, PharmD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

A New Path Forward? Where Are We Going in Managing Hypoparathyroidism?